These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 29541535)

  • 1. Early fine motor impairment and behavioral dysfunction in (Thy-1)-h[A30P] alpha-synuclein mice.
    Ekmark-Lewén S; Lindström V; Gumucio A; Ihse E; Behere A; Kahle PJ; Nordström E; Eriksson M; Erlandsson A; Bergström J; Ingelsson M
    Brain Behav; 2018 Mar; 8(3):e00915. PubMed ID: 29541535
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
    Rabl R; Breitschaedel C; Flunkert S; Duller S; Amschl D; Neddens J; Niederkofler V; Rockenstein E; Masliah E; Roemer H; Hutter-Paier B
    BMC Neurosci; 2017 Jan; 18(1):22. PubMed ID: 28143405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Visualization of early oligomeric α-synuclein pathology and its impact on the dopaminergic system in the (Thy-1)-h[A30P]α-syn transgenic mouse model.
    Behere A; Thörnqvist PO; Winberg S; Ingelsson M; Bergström J; Ekmark-Lewén S
    J Neurosci Res; 2021 Oct; 99(10):2525-2539. PubMed ID: 34292621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Behavioural and dopaminergic changes in double mutated human A30P*A53T alpha-synuclein transgenic mouse model of Parkinson´s disease.
    Kilpeläinen T; Julku UH; Svarcbahs R; Myöhänen TT
    Sci Rep; 2019 Nov; 9(1):17382. PubMed ID: 31758049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Motor dysfunction and gliosis with preserved dopaminergic markers in human alpha-synuclein A30P transgenic mice.
    Gomez-Isla T; Irizarry MC; Mariash A; Cheung B; Soto O; Schrump S; Sondel J; Kotilinek L; Day J; Schwarzschild MA; Cha JH; Newell K; Miller DW; Uéda K; Young AB; Hyman BT; Ashe KH
    Neurobiol Aging; 2003; 24(2):245-58. PubMed ID: 12498958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracranial administration of alpha-synuclein fibrils in A30P-synuclein transgenic mice causes robust synucleinopathy and microglial induction.
    Gentzel RC; Toolan D; Jinn S; Schachter JB; Ma L; Kahle PJ; Smith SM; Marcus JN
    Neurobiol Aging; 2021 Oct; 106():12-25. PubMed ID: 34225000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral characterization of A53T mice reveals early and late stage deficits related to Parkinson's disease.
    Paumier KL; Sukoff Rizzo SJ; Berger Z; Chen Y; Gonzales C; Kaftan E; Li L; Lotarski S; Monaghan M; Shen W; Stolyar P; Vasilyev D; Zaleska M; D Hirst W; Dunlop J
    PLoS One; 2013; 8(8):e70274. PubMed ID: 23936403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Region-specific deficits in dopamine, but not norepinephrine, signaling in a novel A30P α-synuclein BAC transgenic mouse.
    Taylor TN; Potgieter D; Anwar S; Senior SL; Janezic S; Threlfell S; Ryan B; Parkkinen L; Deltheil T; Cioroch M; Livieratos A; Oliver PL; Jennings KA; Davies KE; Ansorge O; Bannerman DM; Cragg SJ; Wade-Martins R
    Neurobiol Dis; 2014 Feb; 62():193-207. PubMed ID: 24121116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mice Expressing A53T/A30P Mutant Alpha-Synuclein in Dopamine Neurons Do Not Display Behavioral Deficits.
    Keomanivong C; Schamp J; Tabakovic E; Thangavel R; Aldridge G; Pieper AA; Narayanan NS
    eNeuro; 2024 Feb; 11(2):. PubMed ID: 38351057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transgenic mice overexpressing tyrosine-to-cysteine mutant human alpha-synuclein: a progressive neurodegenerative model of diffuse Lewy body disease.
    Zhou W; Milder JB; Freed CR
    J Biol Chem; 2008 Apr; 283(15):9863-70. PubMed ID: 18238775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glial A30P alpha-synuclein pathology segregates neurogenesis from anxiety-related behavior in conditional transgenic mice.
    Marxreiter F; Ettle B; May VE; Esmer H; Patrick C; Kragh CL; Klucken J; Winner B; Riess O; Winkler J; Masliah E; Nuber S
    Neurobiol Dis; 2013 Nov; 59():38-51. PubMed ID: 23867236
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Age-related increase of alpha-synuclein oligomers is associated with motor disturbances in L61 transgenic mice.
    Roshanbin S; Aniszewska A; Gumucio A; Masliah E; Erlandsson A; Bergström J; Ingelsson M; Ekmark-Lewén S
    Neurobiol Aging; 2021 May; 101():207-220. PubMed ID: 33639338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
    Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
    Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.
    Pavia-Collado R; Cóppola-Segovia V; Miquel-Rio L; Alarcón-Aris D; Rodríguez-Aller R; Torres-López M; Paz V; Ruiz-Bronchal E; Campa L; Artigas F; Montefeltro A; Revilla R; Bortolozzi A
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Molecular Tweezer Ameliorates Motor Deficits in Mice Overexpressing α-Synuclein.
    Richter F; Subramaniam SR; Magen I; Lee P; Hayes J; Attar A; Zhu C; Franich NR; Bove N; De La Rosa K; Kwong J; Klärner FG; Schrader T; Chesselet MF; Bitan G
    Neurotherapeutics; 2017 Oct; 14(4):1107-1119. PubMed ID: 28585223
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Behavioral defects associated with amygdala and cortical dysfunction in mice with seeded α-synuclein inclusions.
    Stoyka LE; Arrant AE; Thrasher DR; Russell DL; Freire J; Mahoney CL; Narayanan A; Dib AG; Standaert DG; Volpicelli-Daley LA
    Neurobiol Dis; 2020 Feb; 134():104708. PubMed ID: 31837424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A de novo compound targeting α-synuclein improves deficits in models of Parkinson's disease.
    Wrasidlo W; Tsigelny IF; Price DL; Dutta G; Rockenstein E; Schwarz TC; Ledolter K; Bonhaus D; Paulino A; Eleuteri S; Skjevik ÅA; Kouznetsova VL; Spencer B; Desplats P; Gonzalez-Ruelas T; Trejo-Morales M; Overk CR; Winter S; Zhu C; Chesselet MF; Meier D; Moessler H; Konrat R; Masliah E
    Brain; 2016 Dec; 139(Pt 12):3217-3236. PubMed ID: 27679481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice.
    Lindström V; Fagerqvist T; Nordström E; Eriksson F; Lord A; Tucker S; Andersson J; Johannesson M; Schell H; Kahle PJ; Möller C; Gellerfors P; Bergström J; Lannfelt L; Ingelsson M
    Neurobiol Dis; 2014 Sep; 69():134-43. PubMed ID: 24851801
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes.
    Kuo YM; Li Z; Jiao Y; Gaborit N; Pani AK; Orrison BM; Bruneau BG; Giasson BI; Smeyne RJ; Gershon MD; Nussbaum RL
    Hum Mol Genet; 2010 May; 19(9):1633-50. PubMed ID: 20106867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.